A Randomised, Double-blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects with Moderately-to Severely Active Crohn's Disease
Latest Information Update: 11 Oct 2021
At a glance
- Drugs Vercirnon (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Acronyms SHIELD-1
- Sponsors GlaxoSmithKline
- 23 Sep 2015 Results published in the Alimentary Pharmacology and Therapeutics.
- 20 Oct 2014 Results published in a ChemoCentryx media release.
- 23 Aug 2013 Top-line results published in a ChemoCentryx media release.